In Vitro & In Vivo Diagnostic Substances
Standard Industrial Classification: SIC 2835
Industry Insider Sentiment Analysis
The In Vitro & In Vivo Diagnostic Substances sector (SIC 2835) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-08 19:18 | 2023-08-25 | CDIO | Cardio Diagnostics Holdings, Inc. | Dogan Meeshanthini | Director, Officer, 10% owner | BUY | $0.55 | 18,251 | $9,965 | 128,345 |
| 2023-09-08 19:12 | 2023-08-25 | CDIO | Cardio Diagnostics Holdings, Inc. | Dogan Timur | Officer | BUY | $0.55 | 18,251 | $9,965 | 128,345 |
| 2023-09-06 17:01 | - | VNRX | VOLITIONRX LTD | Barnes Phillip | Director | BUY | $1.30 | 5,000 | $6,500 | 24,686 |
| 2023-09-05 23:14 | 2023-08-24 | CDIO | Cardio Diagnostics Holdings, Inc. | Philibert Robert | Director, Officer, 10% owner | BUY | $0.60 | 34,000 | $20,397 | 1,649,792 |
| 2023-09-06 00:01 | 2023-08-31 | IDXX | IDEXX LABORATORIES INC /DE | MAZELSKY JONATHAN JAY | Director, Officer | OPT+S | $512.01 | 13,424 | $6,873,267 | 72,925 |
| 2023-09-01 16:41 | - | VNRX | VOLITIONRX LTD | Faulkes Martin Charles | Director | BUY | $1.28 | 9,716 | $12,436 | 1,673,532 |
| 2023-08-31 16:35 | - | VNRX | VOLITIONRX LTD | Micallef Jacob Vincent | Officer | BUY | $1.25 | 20,000 | $25,062 | 55,000 |
| 2023-09-01 00:17 | 2023-08-29 | IDXX | IDEXX LABORATORIES INC /DE | POLEWACZYK JAMES F | Officer | OPT+S | $510.56 | 22,909 | $11,696,447 | 10,038 |
| 2023-08-28 17:07 | - | VNRX | VOLITIONRX LTD | Micallef Jacob Vincent | Officer | BUY | $1.24 | 20,000 | $24,800 | 235,140 |
| 2023-08-25 18:49 | - | VNRX | VOLITIONRX LTD | Kway Jasmine | Officer | BUY | $1.20 | 5,000 | $6,000 | 10,400 |
| 2023-08-25 18:49 | - | VNRX | VOLITIONRX LTD | Futcher Edward | Director | BUY | $1.22 | 5,000 | $6,100 | 62,936 |
| 2023-08-24 19:00 | - | VNRX | VOLITIONRX LTD | Michel Gaetan | Officer | BUY | $1.23 | 5,000 | $6,150 | 212,997 |
| 2023-08-25 00:58 | 2023-08-24 | MYMD | Q/C TECHNOLOGIES, INC. | Rivard Paul | Officer | BUY | $1.11 | 150,000 | $166,500 | 400,000 |
| 2023-08-23 23:30 | 2023-08-21 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $66.10 | 408 | $26,969 | 90,067 |
| 2023-08-22 23:30 | 2023-08-18 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $65.19 | 1,500 | $97,785 | 90,475 |
| 2023-08-22 17:57 | 2023-08-18 | NEOG | NEOGEN CORP | BOEHM WILLIAM T | Director | OPT+S | $22.59 | 1,500 | $33,891 | 24,509 |
| 2023-08-18 23:21 | 2023-08-17 | MYMD | Q/C TECHNOLOGIES, INC. | Rivard Paul | Officer | BUY | $1.12 | 25,000 | $28,080 | 250,000 |
| 2023-08-17 16:40 | - | VNRX | VOLITIONRX LTD | Butera Salvatore Thomas | Officer | BUY | $1.21 | 8,000 | $9,680 | 69,350 |
| 2023-08-17 23:30 | 2023-08-15 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | Officer | SELL | $68.52 | 10,000 | $685,200 | 108,298 |
| 2023-08-18 02:37 | 2023-08-15 | IDXX | IDEXX LABORATORIES INC /DE | AYERS JONATHAN W | Director | SELL | $0.00 | 492 | $0 | 135,547 |
| 2023-08-16 19:28 | - | VNRX | VOLITIONRX LTD | Reynolds Cameron John | Director, Officer | BUY | $1.22 | 10,000 | $12,200 | 1,494,518 |
| 2023-08-16 00:35 | 2023-08-11 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Director, Officer | SELL | $68.58 | 10,950 | $750,982 | 329,467 |
| 2023-08-15 23:54 | 2023-08-11 | LNTH | Lantheus Holdings, Inc. | Niedzwiecki Daniel | Officer | SELL | $67.93 | 4,297 | $291,895 | 66,295 |
| 2023-08-08 00:04 | 2023-08-03 | IDXX | IDEXX LABORATORIES INC /DE | Lane Michael | Officer | OPT+S | $510.00 | 16,027 | $8,173,770 | 4,034 |
| 2023-08-03 00:19 | 2023-07-31 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Director | SELL | $42.33 | 265 | $11,217 | 12,261 |
| 2023-07-27 02:28 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Fralick Celeste Rachelle | Director | BUY | $3.98 | 754 | $3,001 | 12,032 |
| 2023-07-26 23:28 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Vos Ellen O'Connor | Director | BUY | $3.98 | 3,769 | $15,001 | 32,878 |
| 2023-07-26 00:03 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Parnell Winfred | Director | BUY | $3.98 | 6,281 | $24,998 | 31,513 |
| 2023-07-26 00:11 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Phan Ryan Thinh | Officer | BUY | $3.98 | 628 | $2,499 | 3,939 |
| 2023-07-25 23:58 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Merchant Minh Hoang | Officer | BUY | $3.98 | 754 | $3,001 | 980 |
| 2023-07-26 00:16 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Sandford Nicole | Director, Officer | BUY | $3.98 | 12,563 | $50,001 | 134,665 |
| 2023-07-26 00:20 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Cavanaugh Stefanie L. | Director | BUY | $3.98 | 6,281 | $24,998 | 34,904 |
| 2023-07-26 00:39 | 2023-07-24 | AWH | Aspira Women's Health Inc. | SCHULER JACK W | 10% owner | BUY | $2.75 | 181,800 | $499,950 | 1,883,656 |
| 2023-07-25 01:53 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Hombeck Torsten | Officer | BUY | $3.98 | 754 | $3,001 | 754 |
| 2023-07-25 01:49 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Herchuk Jannie Prestridge | Director | BUY | $3.98 | 8,794 | $35,000 | 23,833 |
| 2023-07-25 01:58 | 2023-07-24 | AWH | Aspira Women's Health Inc. | Jordan Veronica GH | Director | BUY | $3.98 | 3,769 | $15,001 | 34,575 |
| 2023-07-21 23:30 | 2023-07-19 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $90.87 | 1,752 | $159,209 | 59,767 |
| 2023-07-11 00:21 | 2023-07-06 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Director | SELL | $39.30 | 1,867 | $73,373 | 12,526 |
| 2023-07-06 22:34 | 2023-07-03 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | Officer | SELL | $40.51 | 360 | $14,584 | 45,146 |
| 2023-06-26 17:27 | 2023-04-25 | NYMX | NYMOX PHARMACEUTICAL CORP | Robinson James George | Director, 10% owner | BUY | $0.46 | 80,000 | $36,800 | 4,782,065 |
| 2023-06-23 00:52 | 2023-06-20 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | Officer | OPT+S | $45.00 | 5,000 | $225,000 | 45,146 |
| 2023-06-16 03:13 | 2023-06-14 | OCX | Insight Molecular Diagnostics Inc. | KINGSLEY ALFRED D | Director | BUY | $0.21 | 30,000 | $6,447 | 469,111 |
| 2023-06-14 23:55 | 2023-06-13 | TKNO | Alpha Teknova, Inc. | Hood Lisa | Officer | SELL | $3.80 | 11,400 | $43,268 | 33,834 |
| 2023-06-06 17:14 | - | VNRX | VOLITIONRX LTD | Butera Salvatore Thomas | Officer | BUY | $1.59 | 10,000 | $15,900 | 61,350 |
| 2023-06-03 01:15 | 2023-06-02 | MYGN | MYRIAD GENETICS INC | SPIEGELMAN DANIEL K | Director | SELL | $23.01 | 8,638 | $198,760 | 40,493 |
| 2023-06-02 00:42 | 2023-05-30 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Bencich John | Director, Officer | BUY | $5.50 | 5,000 | $27,500 | 66,730 |
| 2023-06-01 00:16 | 2023-05-26 | TKNO | Alpha Teknova, Inc. | Davis Ted | Director, 10% owner | BUY | $3.22 | 2,000 | $6,430 | 1,888,419 |
| 2023-06-01 00:16 | 2023-05-26 | TKNO | Alpha Teknova, Inc. | Davis Irene | Director, 10% owner | BUY | $3.22 | 2,000 | $6,430 | 1,888,419 |
| 2023-05-26 19:23 | 2023-05-24 | BMRA | BIOMERICA INC | Irani Zackary S. | Director, Officer | BUY | $1.59 | 700 | $1,115 | 1,020,560 |
| 2023-05-23 01:47 | 2023-05-18 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $97.93 | 1,500 | $146,895 | 92,743 |
Sector-Wide Insider Alpha
Analyzing insider movements across the In Vitro & In Vivo Diagnostic Substances sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2835) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in In Vitro & In Vivo Diagnostic Substances
Every transaction in the In Vitro & In Vivo Diagnostic Substances industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.